- New drug therapies offer hope to multiple myeloma patients
A nice general article on myeloma and VELCADE. (from the Carolina News)
- Millennium Receives Assignment of Medicare Code for VELCADETM
Hospitals may obtain reimbursement for VELCADE injections under the hospital outpatient prospective payment system (OPPS) effective October 1, 2003.
- A 'monstrous' drug hurdle
Pharmion to market thalidomide to Europe as cancer fighter. (from Denver Post)
- Jury selection to begin in IBM cancer lawsuit
"According to a 'corporate mortality file,' an unusually large number of workers were struck with lymph, blood, breast and brain cancers, as well as non-Hodgkin's lymphoma, leukemia and myeloma in their 30s, 40s and 50s." (from the New York Times. The quote is from an earlier article in The Detroit News.)
- Cell `janitors' tag unwanted substances for removal
This waste-disposal apparatus is known as the ubiquitin system because it's ubiquitous, meaning everywhere. Tagged substances are executed by a proteasome. Drugs that control proteasome are already in clinical trials for the treatment of myeloma. (from Knight Ridder)
- EUROCARE 3 - new European cancer survival figures
Survival figures for cancer in Europe show large differences between countries more than can reasonably be accounted for by artefact, bias or chance (from EurekAlert)
- Message from the Editor of the Myeloma Minute
The Minute has been on hiatus for the last couple of weeks while the Minute office was being rehabilitated and remodeled. But we're back now, and ready and eager to go. After this week, the Minute will appear in your e-mailbox every Friday. Thank you for your patience.
What's New in Myeloma Research:
- Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma
Ranjit K. Dasgupta, Peter J. Adamson, Faith E. Davies, Sara Rollinson, Philippa L. Roddam, A. John Ashcroft, Ann M. Dring, James A. L. Fenton, J. Anthony Child, James M. Allan, and IMF Scientific Advisor Gareth J. Morgan
Researchers assessed the impact of GSTP1 codon 105 polymorphisms in 222 patients entered into a myeloma VII trial (comparing standard-dose chemotherapy with high-dose therapy).
- Aton Pharma, Inc. Receives Orphan Drug Designation for SAHA in Multiple Myeloma and Initiates Phase I Trial
It is expected that up to 34 patients will be enrolled in the trial. (from Yahoo Finance)
- Aastrom Biosciences Receives NIH Grant for Dendritic Cell Vaccine Research
In related activities to this preclinical study for an ovarian cancer dendritic cell vaccine, Aastrom is preparing to begin dendritic cell clinical studies in collaboration with Stanford University for multiple myeloma cancer.
- Callisto Pharmaceuticals Announces Filing of IND (Investigational New Drug) with FDA on Atiprimod for Multiple Myeloma
The drug is now entering clinical trials based on a wide range of compelling preclinical data for myeloma. (from BusinessWire)
- Salmedix Announces the Initiation of a Phase II/III Clinical Program for Non-Hodgkin's Lymphoma
Although its product, SDX-105, is new to patients in North America, it has been used in Germany to treat tens of thousands of cancer patients with other cancers, including myeloma.
- Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
Yamashita K, Iwasaki T, Tsujimura T, Sugihara A, Yamada N, Ueda H, Okamura H, Futani H, Maruo S, Terada N.
Results indicate that mIL-18 inhibited the lodging and subsequent growth of multiple myeloma cells in the bone marrow, and suggest that IL-18 is worth investigating further as to its usefulness as a therapy for multiple myeloma.
- University of Bologna; G-CSF-primed BM autografts improve hematopoietic recovery in some cancer patients
Researchers concluded that G-CSF-primed BM induces effective multilineage hematopoietic recovery after high-dose chemotherapy and can be safely used in patients with poor stem cell mobilization.
- EntreMed selects Panzem formulation.
These new formulations, all orally administered, are designed to increase the amount of Panzem that circulates in the patient's bloodstream by increasing absorption of the drug candidate. Orally administered Panzem has demonstrated anticancer activity in patients with myeloma.
- NeoRx and FDA Reach Agreement on STR Phase III Registration Trial Through Special Protocol Assessment
The phase III trial planned under the SPA will be a randomized, controlled study of STR in patients with primary refractory multiple myeloma. The trial is expected to enroll approximately 240 evaluable patients, half on the experimental arm and half on the control arm.
What's New in Clinical Trials:
If you would like to browse trials currently open for enrollment, visit the Clinical Trials page of the IMF web site. Among the links, you will find CenterWatch and EmergingMed. The IMF has entered into partnerships with them to assist you in matching trials to your particular patient profile (i.e., stage of disease, previous treatment, how well you are able to carry out the activities of daily living, etc.) and by doing so, increase your chances of being eligible. You can also learn more about clinical trials by reviewing materials from the National Cancer Institute.
- Focus on seniors' drug needs shortchanges other worries
Some seniors who exchange the new Medicare plan for the drug coverage they now get through former employers or separate health policies would see their out-of-pocket expenses rise, the Senate Budget Committee reports. And as many as 37% of seniors who now get a drug benefit from former employers could lose it, according to the Congressional Budget Office. But that's only part of the problem. (an Op Ed piece from USA Today)
See related article: Insurers Seek Changes in Prescription Drug Plans
Concern that insurers won't participate has given the industry added political leverage. (from Newhouse News Service)
Quality of Life Update:
Upcoming Seminars and Conferences:
FUNdraising Made Easy
You know you want to do something, but deciding on what to do can be confusing. The IMF can help. This year, our members really rallied 'round the cause, picked up the gauntlet, and raised a lot of money for myeloma research and programs.
We are already getting calls from new members who want to join in the effort and hold an event in 2004. Suzanne Battaglia is waiting for your call. She is here to help you plan and execute your event, so please write, call or email (SBattaglia@myeloma.org) so that you can get on our Calendar of Events!
See what you can do in your community to help further the goal of finding the cure!
Items of Interest:
- Understanding Thalidomide Therapy on the Web
Read it on the web or download and print the PDF document. Available in English, Spanish, French, German, and Italian.
- The National Cancer Institute (NCI) Office of Education and Special Initiatives is looking for patients, family caregivers, and physicians who are interested in participating in telephone focus groups and in-depth interviews. Payment will be provided to all participants.
- BANK ON A CURE®
BANK ON A CURE is an innovative and powerful concept designed to establish a method to find new treatments for multiple myeloma and other related diseases as well as the possibility of new cures, while customizing care for current patients.
- Myeloma Matrix
The Myeloma Matrix provides updated information about drugs beginning with pre-clinical developments and tracks drugs as they proceed through Phases I III of clinical trials, drugs that have been FDA approved, and information on trials that are being conducted by NCI- sponsored cooperative groups as well as other myeloma study groups. The online version is updated regularly. If you would like to have a printed copy, call the toll-free hotline (800) 452-2873.
- International Prognostic Index
The International Myeloma Foundation is proud to sponsor the International Prognostic Index (IPI) Classification for Multiple Myeloma. Nearly twenty myeloma institutions from around the world are collaborating to create an updated staging system for multiple myeloma.
- NexCura Cancer Profiler
The Cancer Profiler is a free service (no hidden fees or charges). Its tools provide you with information specific to your cancer diagnosis to help you make more informed treatment decisions along with your physician.
- Expert Opinions on Multiple Myeloma
A multimedia, CME-accredited program for physicians with the chance to see world-renowned myeloma specialists sharing their knowledge, discussing treatment choices, and comparing their perspectives on controversial issues in multiple myeloma and related diseases.
- Myeloma At The Movies
It has been our goal to bring our Patient & Family Seminars to people around the country who might not be able to attend an actual meeting, so we have set up a video lending library.
- HealthTalk's Multiple Myeloma Education Network
Put this site in your favorites folder.
Shop for the IMF!
Many of the internet's most popular merchants will donate a portion of your purchases to the IMF if you enter their sites using the links on our Shop For The IMF page. You can also use the special shortcut URLs listed below:
So, Shop For The IMF by using these links to the same get great service and low prices you're used to while helping support the IMF!
Help Us Help Others...
As a non-profit organization, the IMF is completely dependent on the support of our members. Please consider showing your support by making a tax-deductible donation today. Donations in honor of a friend or family member make great gifts and are a wonderful way to celebrate a special occasion. You can donate online or by calling the IMF at (800) 452-CURE. We sincerely thank you for your support.
View Back Issues Online...
New to the IMF Myeloma Minute? See what you've been missing by viewing previous issues online!
To unsubscribe from the Myeloma Minute, click here
Tell A Friend...
The Myeloma Minute is a great way to stay abreast of the latest developments within the myeloma community. We hope you'll share this information with friends, family members and physicians and encourage them to sign up for their own copy by forwarding this message. New users can register by clicking here.